AAV9 U7snRNA Gene Therapy to Treat Boys With DMD Exon 2 Duplications

study id #: NCT04240314

condition: Duchenne Muscular Dystrophy

status: enrolling by invitation

purpose:

Open-label, single dose clinical trial of scAAV9.U7.ACCA via peripheral limb vein injection for Duchenne muscular dystrophy boys who have a duplication of exon 2.

intervention: scAAV9.U7.ACCA

mechanism of action: Exon-skipping to promote dystrophin production

results: https://clinicaltrials.gov/ct2/show/results/NCT04240314

last updated: February 01, 2020

start date: January 15, 2020

estimated completion: January 15, 2023

phase of development: Phase 1/Phase 2

size / enrollment: 3

study description:
The proposed clinical trial is a systemic (intravenous) delivery of scAAV9.U7.ACCA for DMD patients with a duplication of exon 2 in the DMD gene. Preclinical data shows that the small nuclear RNA (snRNA) construct delivered by the scAAV9.U7.ACCA vector causes significant skipping of exon 2, resulting in exclusion of the exon from the mature messenger RNA (mRNA) with a high degree of efficiency, leading to mRNA containing only a single exon 2 (wild type [WT] mRNA) or no copies of exon 2 (Del2 mRNA). Translation of the wild-type mRNA results in entirely normal dystrophin protein, whereas translation of the Del2 mRNA via translational initiation of an internal ribosome entry sequence, or IRES) results in a highly functional isoform expressed in patients known to walk into their eighth decade.
The study is designed as an open-label trial to assess safety and obtain preliminary efficacy data. scAAV9.U7.ACCA will be delivered to the systemic circulation via peripheral limb vein.

primary outcomes:

• Monitoring for the development of unacceptable toxicity. [ Time Frame: 2 years ]
  Unacceptable toxicity is defined as the occurrence of two or more unexpected Grade III or higher treatment-related toxicities, as defined by CTCAE 5.0.

secondary outcomes:

• Change in dystrophin expression from baseline following treatment with scAAV9.U7.ACCA. [ Time Frame: 1 year ]
  Expression of dystrophin will be measured by immunofluorescent staining in muscle biopsies taken before and after gene therapy.
  
• Change in dystrophin expression from baseline following treatment with scAAV9.U7.ACCA. [ Time Frame: 1 year ]
  Expression of dystrophin will be quantified by western blotting in muscle biopsies taken before and after gene therapy.
  
• Changes in exon 2 inclusion in the dystrophin mRNA transcript. [ Time Frame: 1 year ]
  Exon 2 inclusion will be measured using RT-PCR analysis.

inclusion criteria:

• Age greater than 6 months and less than 14 years
• Confirmed duplication of exon 2 in the DMD gene using a clinically accepted technique that completely defines the mutation
• Pre-ambulant (not yet walking) or ambulant (as defined by the ability to walk 10 meters without assistance)
• Males of any ethnic group will be eligible
• Ability to cooperate with muscle testing
• In subjects age 4 and above, stable dose and regimen of corticosteroid therapy (prednisone, deflazacort, or their generic forms) for at least 12 weeks prior to gene transfer.

exclusion criteria:
• Active viral infection based on clinical observations
• Symptoms or signs of cardiomyopathy, including:
- Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
- Echocardiogram with ejection fraction below 40%
• Serological evidence of HIV infection, or Hepatitis B or C infection
• Diagnosis of (or ongoing treatment for) an autoimmune disease
• Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL
• Concomitant illness or requirement for chronic drug treatment that in the opinion of the SI creates unnecessary risks for gene transfer
• AAV9 binding antibody titers ≥ 1:400 as determined by ELISA immunoassay
• Abnormal laboratory values in the clinically significant range as listed in Table 7, based upon normal values in the Nationwide Children's Hospital Laboratory.

sponsor: Megan Waldrop

investigators: Megan Waldrop, MD

• United States, Ohio
  Nationwide Children’s Hospital